Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28.5M
-
Number of holders
-
26
-
Total 13F shares, excl. options
-
8.63M
-
Shares change
-
+3.96M
-
Total reported value, excl. options
-
$18.1M
-
Value change
-
+$8.21M
-
Number of buys
-
14
-
Number of sells
-
-11
-
Price
-
$2.10
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q1 2018
32 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q1 2018.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 26 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.63M shares
of 28.5M outstanding shares and own 30.29% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (7.56M shares), VANGUARD GROUP INC (356K shares), BlackRock Inc. (205K shares), Artal Group S.A. (150K shares), BRIDGEWAY CAPITAL MANAGEMENT INC (115K shares), NORTHERN TRUST CORP (44.1K shares), Destination Wealth Management (29.7K shares), GOLDMAN SACHS GROUP INC (29.2K shares), GEODE CAPITAL MANAGEMENT, LLC (23.9K shares), and STATE STREET CORP (18.2K shares).
This table shows the top 26 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.